BR112014003214A2 - polimorfos inibidores de cinase - Google Patents

polimorfos inibidores de cinase

Info

Publication number
BR112014003214A2
BR112014003214A2 BR112014003214A BR112014003214A BR112014003214A2 BR 112014003214 A2 BR112014003214 A2 BR 112014003214A2 BR 112014003214 A BR112014003214 A BR 112014003214A BR 112014003214 A BR112014003214 A BR 112014003214A BR 112014003214 A2 BR112014003214 A2 BR 112014003214A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitor
polymorphs
inhibitor polymorphs
kinase
inhibitor
Prior art date
Application number
BR112014003214A
Other languages
English (en)
Portuguese (pt)
Inventor
Martin Michael
Ren Pingda
Original Assignee
Intellikine Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47669006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014003214(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intellikine Llc filed Critical Intellikine Llc
Publication of BR112014003214A2 publication Critical patent/BR112014003214A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112014003214A 2011-08-11 2012-08-10 polimorfos inibidores de cinase BR112014003214A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161522624P 2011-08-11 2011-08-11
PCT/US2012/050453 WO2013023184A1 (en) 2011-08-11 2012-08-10 Kinase inhibitor polymorphs

Publications (1)

Publication Number Publication Date
BR112014003214A2 true BR112014003214A2 (pt) 2017-03-14

Family

ID=47669006

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003214A BR112014003214A2 (pt) 2011-08-11 2012-08-10 polimorfos inibidores de cinase

Country Status (25)

Country Link
US (1) US20150065524A1 (https=)
EP (1) EP2741749A4 (https=)
JP (1) JP2014521726A (https=)
KR (1) KR20140079368A (https=)
CN (1) CN103957918A (https=)
AU (1) AU2012294202B2 (https=)
BR (1) BR112014003214A2 (https=)
CA (1) CA2844742A1 (https=)
CL (1) CL2014000343A1 (https=)
CO (1) CO6960542A2 (https=)
CR (1) CR20140082A (https=)
DO (1) DOP2014000027A (https=)
EA (1) EA027970B1 (https=)
EC (1) ECSP14013236A (https=)
HK (1) HK1199203A1 (https=)
IL (1) IL230850A0 (https=)
MX (1) MX2014001662A (https=)
MY (1) MY186267A (https=)
PE (1) PE20141358A1 (https=)
PH (1) PH12014500331A1 (https=)
RU (1) RU2636588C2 (https=)
SG (2) SG2014009492A (https=)
TN (1) TN2014000063A1 (https=)
WO (1) WO2013023184A1 (https=)
ZA (1) ZA201401211B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0406647A (pt) 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CA2854926A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途
CN105899232A (zh) 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
ES2636646B1 (es) * 2016-04-05 2018-08-03 Universidade De Santiago De Compostela NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
BR112019010511A2 (pt) 2016-11-23 2019-09-17 Bayer Ag derivados de heterociclo bicíclico fundido como pesticidas
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
PL3737685T3 (pl) * 2018-01-09 2023-10-02 Halcyon Labs Private Limited Sposób wytwarzania kryzaborolu i jego związków pośrednich
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
TWI674262B (zh) * 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式

Also Published As

Publication number Publication date
RU2014109023A (ru) 2015-09-20
AU2012294202A1 (en) 2014-03-06
IL230850A0 (en) 2014-03-31
EA201490446A1 (ru) 2014-05-30
EP2741749A4 (en) 2015-04-15
EP2741749A1 (en) 2014-06-18
AU2012294202B2 (en) 2017-02-23
JP2014521726A (ja) 2014-08-28
PE20141358A1 (es) 2014-10-12
CO6960542A2 (es) 2014-05-30
ECSP14013236A (es) 2014-06-30
SG2014009492A (en) 2014-09-26
CR20140082A (es) 2014-06-03
ZA201401211B (en) 2015-12-23
EA027970B1 (ru) 2017-09-29
SG10201606288TA (en) 2016-09-29
US20150065524A1 (en) 2015-03-05
PH12014500331A1 (en) 2014-03-31
NZ622208A (en) 2016-04-29
CA2844742A1 (en) 2013-02-14
MX2014001662A (es) 2014-08-26
RU2636588C2 (ru) 2017-11-24
MY186267A (en) 2021-07-01
TN2014000063A1 (en) 2015-07-01
KR20140079368A (ko) 2014-06-26
HK1199203A1 (en) 2015-06-26
CN103957918A (zh) 2014-07-30
CL2014000343A1 (es) 2014-10-17
WO2013023184A1 (en) 2013-02-14
DOP2014000027A (es) 2014-07-15

Similar Documents

Publication Publication Date Title
FR25C1006I2 (fr) Inhibiteurs de pyrazolyl-quinoxaline kinase
BR112014003214A2 (pt) polimorfos inibidores de cinase
EP2710007A4 (en) Kinase inhibitors
CO6970602A2 (es) Inhibidores de quinasa
HUE036259T2 (hu) Inhibitor vegyületek
LT3181567T (lt) Pirazolpirimidino junginiai kaip kinazės slopikliai
CO6950481A2 (es) Inhibidores de proteínas quinasas
HUE047888T2 (hu) Glükozilceramid-szintáz-inhibitor
CO6900145A2 (es) Compuesto de ciclopropanoamina
HRP20181786T1 (hr) Inhibitori aktivacije t-stanica
HRP20181533T1 (hr) Antikancerogeni piridopirazini putem inhibitora fgfr kinaze
EP2684880A4 (en) DISPIROPYRROLIDINDERIVAT
CO6791562A2 (es) Compuestos antivirales
BR112014007781A2 (pt) compostos anti-virais
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
IL230561A0 (en) Inhibitors of bruton's tyrosine kinsae
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112014012016A2 (pt) compostos
CO6910197A2 (es) Compuestos novedosos
EP2776428A4 (en) KINASEHEMMERPOLYMORPHE
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
CO6990735A2 (es) Inhibidores de pirazina cinasa
CO6960557A2 (es) Derivados de 2-yodo-imidazol
BR112014007599A2 (pt) compostos anti-virais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.